Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Sep 14 - Sep 16, 2020H.C. WAINWRIGHT 22ND ANNUAL GLOBAL INVESTMENT CONFERENCE
Jun 22, 2020AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) VIRTUAL ANNUAL MEETING II
Jun 12, 2020 at 8:00 AM EDTKOL Call on Intratumoral Neoadjuvant Therapy with Self-Delivering RNAi